JP2008506750A - チオール基を含む化合物の排出ポンプ抑制剤としての使用 - Google Patents
チオール基を含む化合物の排出ポンプ抑制剤としての使用 Download PDFInfo
- Publication number
- JP2008506750A JP2008506750A JP2007521944A JP2007521944A JP2008506750A JP 2008506750 A JP2008506750 A JP 2008506750A JP 2007521944 A JP2007521944 A JP 2007521944A JP 2007521944 A JP2007521944 A JP 2007521944A JP 2008506750 A JP2008506750 A JP 2008506750A
- Authority
- JP
- Japan
- Prior art keywords
- drug
- use according
- thiol groups
- glutathione
- thiolated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003396 thiol group Chemical group [H]S* 0.000 title claims abstract description 40
- 150000001875 compounds Chemical class 0.000 title claims description 58
- 239000003112 inhibitor Substances 0.000 title description 8
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims abstract description 74
- 239000003814 drug Substances 0.000 claims abstract description 53
- 229940079593 drug Drugs 0.000 claims abstract description 42
- 108010024636 Glutathione Proteins 0.000 claims abstract description 37
- 229960003180 glutathione Drugs 0.000 claims abstract description 37
- 210000004877 mucosa Anatomy 0.000 claims abstract description 31
- 239000003889 eye drop Substances 0.000 claims description 6
- 239000011859 microparticle Substances 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 239000003826 tablet Substances 0.000 claims description 6
- 229940012356 eye drops Drugs 0.000 claims description 5
- 239000000243 solution Substances 0.000 claims description 5
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 4
- -1 antibiotic Substances 0.000 claims description 4
- 239000001913 cellulose Substances 0.000 claims description 4
- 229920002678 cellulose Polymers 0.000 claims description 4
- 229940127291 Calcium channel antagonist Drugs 0.000 claims description 3
- 229920002845 Poly(methacrylic acid) Polymers 0.000 claims description 3
- 108010039918 Polylysine Proteins 0.000 claims description 3
- 229920002125 Sokalan® Polymers 0.000 claims description 3
- 230000003288 anthiarrhythmic effect Effects 0.000 claims description 3
- 230000001857 anti-mycotic effect Effects 0.000 claims description 3
- 239000003416 antiarrhythmic agent Substances 0.000 claims description 3
- 239000003146 anticoagulant agent Substances 0.000 claims description 3
- 229940127219 anticoagulant drug Drugs 0.000 claims description 3
- 239000002543 antimycotic Substances 0.000 claims description 3
- 239000000480 calcium channel blocker Substances 0.000 claims description 3
- 229960001631 carbomer Drugs 0.000 claims description 3
- 239000002105 nanoparticle Substances 0.000 claims description 3
- 229920000724 poly(L-arginine) polymer Polymers 0.000 claims description 3
- 108010011110 polyarginine Proteins 0.000 claims description 3
- 229920000656 polylysine Polymers 0.000 claims description 3
- 229940124599 anti-inflammatory drug Drugs 0.000 claims description 2
- 239000003430 antimalarial agent Substances 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000003995 emulsifying agent Substances 0.000 claims description 2
- 239000005556 hormone Substances 0.000 claims description 2
- 229940088597 hormone Drugs 0.000 claims description 2
- 239000003018 immunosuppressive agent Substances 0.000 claims description 2
- 229940124589 immunosuppressive drug Drugs 0.000 claims description 2
- 239000003589 local anesthetic agent Substances 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 239000003550 marker Substances 0.000 claims description 2
- 239000011159 matrix material Substances 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 210000001215 vagina Anatomy 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121375 antifungal agent Drugs 0.000 claims 1
- 239000003429 antifungal agent Substances 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 230000000973 chemotherapeutic effect Effects 0.000 claims 1
- 230000037406 food intake Effects 0.000 claims 1
- 210000000214 mouth Anatomy 0.000 claims 1
- 210000003928 nasal cavity Anatomy 0.000 claims 1
- 238000010521 absorption reaction Methods 0.000 abstract description 25
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 abstract description 15
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 abstract description 15
- 239000002552 dosage form Substances 0.000 abstract description 13
- 230000000694 effects Effects 0.000 abstract description 13
- 239000000203 mixture Substances 0.000 abstract description 10
- 230000002401 inhibitory effect Effects 0.000 abstract description 8
- 238000009472 formulation Methods 0.000 abstract description 7
- 239000000546 pharmaceutical excipient Substances 0.000 abstract description 7
- 239000000126 substance Substances 0.000 abstract description 4
- 206010028980 Neoplasm Diseases 0.000 abstract description 3
- 201000011510 cancer Diseases 0.000 abstract description 3
- 210000004400 mucous membrane Anatomy 0.000 abstract description 3
- 239000002246 antineoplastic agent Substances 0.000 abstract description 2
- 229940044683 chemotherapy drug Drugs 0.000 abstract description 2
- 239000000824 cytostatic agent Substances 0.000 abstract description 2
- 239000006201 parenteral dosage form Substances 0.000 abstract description 2
- 230000001085 cytostatic effect Effects 0.000 abstract 1
- 229920006295 polythiol Polymers 0.000 description 21
- 229920001661 Chitosan Polymers 0.000 description 11
- 230000028327 secretion Effects 0.000 description 11
- 239000004480 active ingredient Substances 0.000 description 10
- TUFFYSFVSYUHPA-UHFFFAOYSA-M rhodamine 123 Chemical compound [Cl-].COC(=O)C1=CC=CC=C1C1=C(C=CC(N)=C2)C2=[O+]C2=C1C=CC(N)=C2 TUFFYSFVSYUHPA-UHFFFAOYSA-M 0.000 description 10
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 10
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- MFCQLXPICKBECH-LTSABEDGSA-N (3R,4R,5S,6R)-3-amino-6-(hydroxymethyl)oxane-2,4,5-triol (2R)-2-amino-3-sulfanylpropanoic acid Chemical compound SC[C@H](N)C(O)=O.N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MFCQLXPICKBECH-LTSABEDGSA-N 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000005945 translocation Effects 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 4
- 108010036949 Cyclosporine Proteins 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 229960001265 ciclosporin Drugs 0.000 description 4
- 210000004087 cornea Anatomy 0.000 description 4
- 229930182912 cyclosporin Natural products 0.000 description 4
- 238000012377 drug delivery Methods 0.000 description 4
- 229960003276 erythromycin Drugs 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 229930012538 Paclitaxel Natural products 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 229960001592 paclitaxel Drugs 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 3
- 229930105110 Cyclosporin A Natural products 0.000 description 2
- 229940049937 Pgp inhibitor Drugs 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000002748 glycoprotein P inhibitor Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 229940100652 nasal gel Drugs 0.000 description 2
- 229940126701 oral medication Drugs 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 150000003573 thiols Chemical class 0.000 description 2
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- PXZLYPLSGXGBMZ-UHFFFAOYSA-N 3,5-dihydroxy-3-(2-hydroxyethyl)-2-(hydroxymethyl)pentanamide Chemical compound OCCC(O)(C(C(O)=N)CO)CCO PXZLYPLSGXGBMZ-UHFFFAOYSA-N 0.000 description 1
- 102100028161 ATP-binding cassette sub-family C member 2 Human genes 0.000 description 1
- 102100022595 Broad substrate specificity ATP-binding cassette transporter ABCG2 Human genes 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010090306 Member 2 Subfamily G ATP Binding Cassette Transporter Proteins 0.000 description 1
- 108010066419 Multidrug Resistance-Associated Protein 2 Proteins 0.000 description 1
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 description 1
- AOBORMOPSGHCAX-UHFFFAOYSA-N Tocophersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 230000000078 anti-malarial effect Effects 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000002011 intestinal secretion Anatomy 0.000 description 1
- 239000013563 matrix tablet Substances 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229940113116 polyethylene glycol 1000 Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960000311 ritonavir Drugs 0.000 description 1
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 1
- 229960001852 saquinavir Drugs 0.000 description 1
- QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/717—Celluloses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/795—Polymers containing sulfur
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
- A61K38/063—Glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AT12502004 | 2004-07-22 | ||
| PCT/EP2005/053395 WO2006008270A1 (de) | 2004-07-22 | 2005-07-14 | Verwendung von thiolgruppen-hältigen verbindungen als efflux-pumpen-hemmer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008506750A true JP2008506750A (ja) | 2008-03-06 |
| JP2008506750A5 JP2008506750A5 (enExample) | 2008-08-14 |
Family
ID=34981500
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007521944A Pending JP2008506750A (ja) | 2004-07-22 | 2005-07-14 | チオール基を含む化合物の排出ポンプ抑制剤としての使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20080200563A1 (enExample) |
| EP (1) | EP1768676A1 (enExample) |
| JP (1) | JP2008506750A (enExample) |
| CN (1) | CN101035547A (enExample) |
| AU (1) | AU2005263729B2 (enExample) |
| CA (1) | CA2574232A1 (enExample) |
| WO (1) | WO2006008270A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2107913B1 (en) | 2006-12-22 | 2012-02-15 | Croma-Pharma Gesellschaft m.b.H. | Use of thiolated polysaccharides for tissue augmentation |
| EP2296637B1 (en) | 2008-04-24 | 2014-04-02 | Medtronic, Inc | Chitosan-containing protective composition |
| US8653319B2 (en) | 2008-04-24 | 2014-02-18 | Medtronic, Inc. | Cold ionizing radiation sterilization |
| CA2721937C (en) | 2008-04-24 | 2016-07-12 | Medtronic, Inc. | Protective gel based on chitosan and oxidized polysaccharide |
| CA2722145A1 (en) | 2008-04-24 | 2009-10-29 | Medtronic, Inc. | Rehydratable thiolated polysaccharide particles and sponge |
| EP2405934B1 (en) | 2009-03-12 | 2014-03-26 | Nordic Bioscience A/S | Treatment of diabetes and metabolic syndrome |
| CA2854175A1 (en) | 2011-11-02 | 2013-05-10 | Keybioscience Ag | Peptide analogs for treating diseases and disorders |
| SI3095484T1 (en) | 2011-11-02 | 2018-08-31 | Keybioscience Ag | Calcitonin mimetics for the treatment of diseases and disorders |
| BR112016010643A2 (pt) | 2013-11-14 | 2017-12-05 | Keybioscience Ag | peptídeo |
| GB201500263D0 (en) | 2015-01-08 | 2015-02-25 | Keybioscience Ag | Calcitonin analogues for treating diseases and disorders |
| GB201704429D0 (en) | 2017-03-21 | 2017-05-03 | Keybioscience Ag | Calcitonin mimetics for treating diseases and disorders |
| GB201707955D0 (en) | 2017-05-18 | 2017-07-05 | Keybioscience Ag | Dual amylin and calcitonin receptor agonists for treating diseases and disorders |
| GB201813678D0 (en) | 2018-08-22 | 2018-10-03 | Keybioscience Ag | Acylated calcitonin mimetics |
| GB201813677D0 (en) | 2018-08-22 | 2018-10-03 | Keybioscience Ag | Calcitonin mimetics for treating diseases and disorders |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07507325A (ja) * | 1992-06-24 | 1995-08-10 | ベーリンガー マンハイム イタリア エス．ピー．エイ． | 化学保護剤としてのグルタチオン |
| JPH1045502A (ja) * | 1996-05-07 | 1998-02-17 | Wisconsin Alumni Res Found | 臓器保存及び心臓麻痺性の薬としての使用のためのタキソール合成物 |
| JPH10502085A (ja) * | 1994-06-23 | 1998-02-24 | アルコン・ラボラトリーズ・インコーポレーテッド | Ｉｏｐを制御するための医薬を含有する眼内潅注溶液 |
| JP2004502728A (ja) * | 2000-07-11 | 2004-01-29 | ハンター−フレミング・リミテッド | 薬学的化合物の還元体の治療的および予防的使用 |
| JP2005298364A (ja) * | 2004-04-07 | 2005-10-27 | Rohto Pharmaceut Co Ltd | アズレン含有水性液剤 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE420733B (sv) * | 1974-05-30 | 1981-10-26 | Exploaterings Ab Tbf | Gelprodukt, innehallande tiosulfatgrupper samt sett for framstellning derav |
| IT1282625B1 (it) * | 1996-02-14 | 1998-03-31 | Zambon Spa | Composizione farmaceutica atta ad inibire la formazione di metastasi tumorali |
-
2005
- 2005-07-14 JP JP2007521944A patent/JP2008506750A/ja active Pending
- 2005-07-14 WO PCT/EP2005/053395 patent/WO2006008270A1/de not_active Ceased
- 2005-07-14 CA CA002574232A patent/CA2574232A1/en not_active Abandoned
- 2005-07-14 CN CNA2005800242315A patent/CN101035547A/zh active Pending
- 2005-07-14 US US11/632,868 patent/US20080200563A1/en not_active Abandoned
- 2005-07-14 EP EP05771836A patent/EP1768676A1/de not_active Withdrawn
- 2005-07-14 AU AU2005263729A patent/AU2005263729B2/en not_active Ceased
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07507325A (ja) * | 1992-06-24 | 1995-08-10 | ベーリンガー マンハイム イタリア エス．ピー．エイ． | 化学保護剤としてのグルタチオン |
| JPH10502085A (ja) * | 1994-06-23 | 1998-02-24 | アルコン・ラボラトリーズ・インコーポレーテッド | Ｉｏｐを制御するための医薬を含有する眼内潅注溶液 |
| JPH1045502A (ja) * | 1996-05-07 | 1998-02-17 | Wisconsin Alumni Res Found | 臓器保存及び心臓麻痺性の薬としての使用のためのタキソール合成物 |
| JP2004502728A (ja) * | 2000-07-11 | 2004-01-29 | ハンター−フレミング・リミテッド | 薬学的化合物の還元体の治療的および予防的使用 |
| JP2005298364A (ja) * | 2004-04-07 | 2005-10-27 | Rohto Pharmaceut Co Ltd | アズレン含有水性液剤 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1768676A1 (de) | 2007-04-04 |
| AU2005263729A1 (en) | 2006-01-26 |
| CN101035547A (zh) | 2007-09-12 |
| US20080200563A1 (en) | 2008-08-21 |
| WO2006008270A1 (de) | 2006-01-26 |
| CA2574232A1 (en) | 2006-01-26 |
| AU2005263729B2 (en) | 2011-01-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chang et al. | Liposomal dexamethasone–moxifloxacin nanoparticle combinations with collagen/gelatin/alginate hydrogel for corneal infection treatment and wound healing | |
| CN102429862B (zh) | 一种聚维酮碘眼用缓释滴眼液 | |
| AU2005263729B2 (en) | Use of compounds containing thiol groups as an efflux pump inhibitor | |
| US11090330B2 (en) | Pharmaceutical solution having a toxicity-reducing effect for antitumor drugs, and pharmaceutical composition comprising same | |
| ES2898348T3 (es) | Composiciones farmacéuticas sólidas que contienen un inhibidor de la integrasa | |
| BG107831A (bg) | Комбинация от лекарства, по-специално хлорпромазин и пентамидин, за лечение на неопластични заболявания | |
| FI87528B (fi) | Foerfarande foer framstaellning av en oral dosenhet av kaliumklorid | |
| AU2008345474B2 (en) | Pharmaceutical compositions containing at least one proteinaceous active ingredient protected against digestive enzymes | |
| CN116999410A (zh) | 具有生物活性亲脂性化合物的聚乙二醇化脂质纳米粒 | |
| KR20160114746A (ko) | 신규 멜록시캄 제제 | |
| CN101193682B (zh) | 包含一种抗病毒、一种抗肿瘤或一种抗寄生虫药以及一种选自香芹醇、麝香草酚、丁香酚、樟醇和香芹酚的活性物质的药物组合物 | |
| US8945627B2 (en) | Micelles for the solubilization of gossypol | |
| EP4210677A1 (en) | Niclosamide particles and uses thereof | |
| US20180015074A1 (en) | Use of mtor inhibitors to prevent and regress edhesions and fibrosis | |
| MX2010006906A (es) | Sistema de suministro de farmaco para la administracion de una substancia farmaceuticamente activa soluble en agua, cationica y anfifilica. | |
| WO2018026379A1 (en) | Phytochemical composition for the treatment of lyme disease | |
| Kang et al. | Mixed micelles with galactose ligands for the oral delivery of berberine to enhance its bioavailability and hypoglycemic effects | |
| WO2022166724A1 (zh) | 一种福多司坦吸入用溶液制剂及其制备方法和用途 | |
| AU2006270094A1 (en) | Prevention and treatment of ophthalmic complications of diabetes | |
| WO2006039268A2 (en) | Pharmaceutical formulations containing vitamin e tpgs molecules that solubilize lipophilic drugs without significant efflux inhibition, and use of such formulations | |
| CA2754281A1 (en) | Antiviral combination of zinc and trimethoprim | |
| RU2282437C1 (ru) | Средство для лечения болезней суставов | |
| CN110151824A (zh) | 一种治疗下咽癌的药物组合物及其制备方法 | |
| BRPI0710564A2 (pt) | agentes anti-cáncer a base de polìmero | |
| US20250177318A1 (en) | Cmt-3 formulations and methods of using the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080626 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080626 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110802 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20111101 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20111109 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20111201 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20111208 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20111228 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120111 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120201 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121002 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20121221 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130107 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130201 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130208 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130301 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130308 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130327 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20131203 |